Quote:
Originally Posted by summersm343
|
Ensemble Real Estate Investments has bulked up on its Philadelphia Navy Yard holdings and paid $83 million for a three-building portfolio.
The purchase of the properties means Ensemble has solidified its presence at the Navy Yard, establishing a critical mass at the site and stepping in where Liberty Property Trust left off. The real estate company now owns or holds interests in nine buildings totaling 1.1 million square feet at the South Philadelphia site and has invested a total of $360 million there.
More than half of its holdings, or five buildings totaling 550,000 square feet and an investment of $155 million, involve buildings that have manufacturing, laboratory, R&D and office space used for the development of immunotherapies, including cell-gene therapy. They house life science companies such as Adaptimmune Therapeutics, which maintains its U.S. headquarters at the Navy Yard, and Iovance Biotherapeutics, which has a manufacturing facility under development.
Long Beach, Calif.-based Ensemble is also part of a team named in July to develop 109 acres that is expected to reshape the next phase of the Navy Yard and it also controls several other sites that can be developed.
In its latest acquisition, the company purchased:
- 400 Rouse Blvd., a 140,000-square-foot office and laboratory building;
- 4751 League Island Blvd., an 82,000-square-foot building; and,
- 150,000-square-foot building at 4701 League Island Blvd.
All of the buildings are leased on a long-term basis to WuXi AppTec, which is one of the largest tenants at the Navy Yard.
"This is a critical component to our portfolio at the Navy Yard and to our growth strategy," said Mark Seltzer, senior vice president of development with Ensemble. "Wuxi is the driver of the life science cluster at the Navy Yard. They serve as the gateway to the new development and next phase of the Navy Yard."
Wuxi located to the Navy Yard in 2004 when it opened a 75,000-square-foot contract testing and manufacturing facility. It continued to grow over the years, adding a non-viral cell therapy manufacturing facilities and, in 2017, established an advanced therapy unit to bolster its U.S.-based cell and gene therapies. Earlier this year, Wuxi moved into 400 Rouse, which houses an advanced therapies testing facility and doubled its testing capacity for gene and cell therapies.
Life science companies prefer these two and three-story buildings that enable them to conduct research and manufacturing on single floors.
"They want to be in a horizontal environment and that's what makes the Navy Yard attractive," Seltzer said. These companies also like the Navy Yard's proximity to Philadelphia International Airport and University City, where there's a labor force from which to draw.
In addition to the Wuxi buildings, Ensemble owns at the Navy Yard a Courtyard by Marriott and four office buildings including One Crescent Drive, 150 Rouse Blvd., 201 Rouse Blvd., and 1200 Intrepid Ave.
Prologis Inc., which acquired Liberty Property earlier this year, was the seller of the Wuxi buildings. Robert Fahey and Jerry Kranzel of CBRE Inc. arranged the transaction.
One of the buildings that had been for sale as part of that portfolio was 4000 S. 26th St., a 55,000-square-foot structure, but Prologis decided not to sell. WuXi is a tenant along with several other companies in the building.